

Ennio Antonio Chiocca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/87650/publications.pdf>

Version: 2024-02-01

180
papers

10,441
citations

53794

45
h-index

36028

97
g-index

184
all docs

184
docs citations

184
times ranked

13894
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. <i>Nature</i> , 2019, 565, 234-239.	27.8	956
2	In vivo magnetic resonance imaging of transgene expression. <i>Nature Medicine</i> , 2000, 6, 351-354.	30.7	811
3	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113.	1.2	543
4	Oncolytic Viruses in Cancer Treatment. <i>JAMA Oncology</i> , 2017, 3, 841.	7.1	426
5	Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. <i>Science Advances</i> , 2018, 4, eaar2766.	10.3	416
6	A Phase I Open-Label, Dose-Escalation, Multi-Institutional Trial of Injection with an E1B-Attenuated Adenovirus, ONYX-015, into the Peritumoral Region of Recurrent Malignant Gliomas, in the Adjuvant Setting. <i>Molecular Therapy</i> , 2004, 10, 958-966.	8.2	401
7	Mechanisms and therapeutic implications of hypermutation in gliomas. <i>Nature</i> , 2020, 580, 517-523.	27.8	374
8	Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. <i>Nature Medicine</i> , 1999, 5, 881-887.	30.7	309
9	Oncolytic Viruses and Their Application to Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2014, 2, 295-300.	3.4	308
10	CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. <i>Scientific Reports</i> , 2015, 5, 11483.	3.3	270
11	Multiplexed Profiling of Single Extracellular Vesicles. <i>ACS Nano</i> , 2018, 12, 494-503.	14.6	256
12	Blood-brain-barrier spheroids as an in vitro screening platform for brain-penetrating agents. <i>Nature Communications</i> , 2017, 8, 15623.	12.8	224
13	Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. <i>Cell</i> , 2021, 184, 1281-1298.e26.	28.9	210
14	Extracellular Vesicles Modulate the Glioblastoma Microenvironment via a Tumor Suppression Signaling Network Directed by miR-1. <i>Cancer Research</i> , 2014, 74, 738-750.	0.9	197
15	A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. <i>Oncotarget</i> , 2016, 7, 27764-27777.	1.8	188
16	Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase I trial. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	170
17	An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. <i>Nature Biotechnology</i> , 1998, 16, 444-448.	17.5	167
18	NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. <i>Nature Medicine</i> , 2012, 18, 1827-1834.	30.7	164

#	ARTICLE	IF	CITATIONS
19	Immunotherapy advances for glioblastoma. <i>Neuro-Oncology</i> , 2014, 16, 1441-1458.	1.2	164
20	The Long Non-coding RNA HIF1A-AS2 Facilitates the Maintenance of Mesenchymal Glioblastoma Stem-like Cells in Hypoxic Niches. <i>Cell Reports</i> , 2016, 15, 2500-2509.	6.4	156
21	Radiation-Induced Targeted Nanoparticle-Based Gene Delivery for Brain Tumor Therapy. <i>ACS Nano</i> , 2019, 13, 4028-4040.	14.6	147
22	Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. <i>Neuro-Oncology</i> , 2016, 18, 1137-1145.	1.2	126
23	Phase 1 Clinical Trial of Intratumoral Reovirus Infusion for the Treatment of Recurrent Malignant Gliomas in Adults. <i>Molecular Therapy</i> , 2014, 22, 1056-1062.	8.2	119
24	A Phase I Trial of Ad.hIFN- β Gene Therapy for Glioma. <i>Molecular Therapy</i> , 2008, 16, 618-626.	8.2	114
25	Advances in local therapy for glioblastoma “taking the fight to the tumour. <i>Nature Reviews Neurology</i> , 2022, 18, 221-236.	10.1	106
26	Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 276-287.	7.0	100
27	Gene Therapy for Brain Tumors. <i>Brain Pathology</i> , 1995, 5, 345-381.	4.1	93
28	Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 290-299.	7.0	88
29	Imaging flow cytometry facilitates multiparametric characterization of extracellular vesicles in malignant brain tumours. <i>Journal of Extracellular Vesicles</i> , 2019, 8, 1588555.	12.2	86
30	Interferon-stimulated Gene 15 (ISG15) and ISG15-linked Proteins Can Associate with Members of the Selective Autophagic Process, Histone Deacetylase 6 (HDAC6) and SQSTM1/p62. <i>Journal of Biological Chemistry</i> , 2015, 290, 1485-1495.	3.4	85
31	Extracellular Vesicles from High-Grade Glioma Exchange Diverse Pro-oncogenic Signals That Maintain Intratumoral Heterogeneity. <i>Cancer Research</i> , 2016, 76, 2876-2881.	0.9	85
32	Glial and myeloid heterogeneity in the brain tumour microenvironment. <i>Nature Reviews Cancer</i> , 2021, 21, 786-802.	28.4	83
33	Belonging to a network “microRNAs, extracellular vesicles, and the glioblastoma microenvironment. <i>Neuro-Oncology</i> , 2015, 17, 652-662.	1.2	78
34	TGF β Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response. <i>Cancer Research</i> , 2015, 75, 5273-5282.	0.9	75
35	Characterization of single microvesicles in plasma from glioblastoma patients. <i>Neuro-Oncology</i> , 2019, 21, 606-615.	1.2	72
36	Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?. <i>Neuro-Oncology</i> , 2019, 21, 14-25.	1.2	69

#	ARTICLE	IF	CITATIONS
37	Perfluoroarene-Based Peptide Macrocycles to Enhance Penetration Across the Blood-Brain Barrier. <i>Journal of the American Chemical Society</i> , 2017, 139, 15628-15631.	13.7	60
38	The multiple protective roles and molecular mechanisms of melatonin and its precursor N-acetylserotonin in targeting brain injury and liver damage and in maintaining bone health. <i>Free Radical Biology and Medicine</i> , 2019, 130, 215-233.	2.9	59
39	Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. <i>Neuro-Oncology</i> , 2021, 23, 356-375.	1.2	59
40	MicroRNA Signatures and Molecular Subtypes of Glioblastoma: The Role of Extracellular Transfer. <i>Stem Cell Reports</i> , 2017, 8, 1497-1505.	4.8	58
41	Immune Checkpoint Inhibition in GBM Primed with Radiation by Engineered Extracellular Vesicles. <i>ACS Nano</i> , 2022, 16, 1940-1953.	14.6	58
42	An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma. <i>Nature Biotechnology</i> , 2019, 37, 45-54.	17.5	56
43	An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma. <i>Nature Communications</i> , 2021, 12, 5908.	12.8	56
44	Cytomegalovirus promotes murine glioblastoma growth via pericyte recruitment and angiogenesis. <i>Journal of Clinical Investigation</i> , 2019, 129, 1671-1683.	8.2	52
45	Neurosurgical Delivery of Chemotherapeutics, Targeted Toxins, Genetic and Viral Therapies in Neuro-Oncology. <i>Journal of Neuro-Oncology</i> , 2004, 69, 101-117.	2.9	50
46	Glucose-Based Regulation of miR-451/AMPK Signaling Depends on the OCT1 Transcription Factor. <i>Cell Reports</i> , 2015, 11, 902-909.	6.4	50
47	Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation. <i>Cancer Gene Therapy</i> , 2000, 7, 1051-1059.	4.6	48
48	Hypofractionated Versus Standard Radiation Therapy With or Without Temozolomide for Older Glioblastoma Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 384-389.	0.8	46
49	The host response to cancer virotherapy. <i>Current Opinion in Molecular Therapeutics</i> , 2008, 10, 38-45.	2.8	46
50	Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial. <i>Neuro-Oncology</i> , 2022, 24, 951-963.	1.2	44
51	STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	44
52	Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus. <i>Molecular Cell</i> , 2020, 78, 1207-1223.e8.	9.7	43
53	MicroRNA-10b inhibition reduces E2F1-mediated transcription and miR-15/16 activity in glioblastoma. <i>Oncotarget</i> , 2015, 6, 3770-3783.	1.8	42
54	Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1344-1355.	1.2	40

#	ARTICLE	IF	CITATIONS
55	Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 2574-2584.	7.0	40
56	Neurosurgical robotics: a review of brain and spine applications. <i>Journal of Robotic Surgery</i> , 2007, 1, 39-43.	1.8	38
57	BKM-120 (Buparlisib): A Phosphatidylinositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma. <i>Scientific Reports</i> , 2016, 6, 20189.	3.3	38
58	HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials. <i>Cancers</i> , 2020, 12, 3514.	3.7	38
59	Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. <i>Neuro-Oncology</i> , 2022, 24, 101-113.	1.2	38
60	Oncolytic Virus-Mediated Immunotherapy: A Combinatorial Approach for Cancer Treatment. <i>Journal of Clinical Oncology</i> , 2015, 33, 2812-2814.	1.6	36
61	Extracellular Vesicles and MicroRNAs: Their Role in Tumorigenicity and Therapy for Brain Tumors. <i>Cellular and Molecular Neurobiology</i> , 2016, 36, 361-376.	3.3	36
62	Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models. <i>Neuro-Oncology</i> , 2017, 19, now253.	1.2	35
63	Molecular responses to immune checkpoint blockade in glioblastoma. <i>Nature Medicine</i> , 2019, 25, 359-361.	30.7	35
64	MicroRNA-Mediated Dynamic Bidirectional Shift between the Subclasses of Glioblastoma Stem-like Cells. <i>Cell Reports</i> , 2017, 19, 2026-2032.	6.4	33
65	Developmental expression of GPR3 in rodent cerebellar granule neurons is associated with cell survival and protects neurons from various apoptotic stimuli. <i>Neurobiology of Disease</i> , 2014, 68, 215-227.	4.4	31
66	Immunotherapy for glioblastoma: on the sidelines or in the game?. <i>Discovery Medicine</i> , 2017, 24, 201-208.	0.5	31
67	Anticancer activity of osmium(VI) nitrido complexes in patient-derived glioblastoma initiating cells and in vivo mouse models. <i>Cancer Letters</i> , 2018, 416, 138-148.	7.2	29
68	Deep Sylvian Fissure Meningioma without Dural Attachment in an Adult. <i>Neurosurgery</i> , 1994, 35, 944-946.	1.1	28
69	Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses. <i>Scientific Reports</i> , 2020, 10, 5095.	3.3	28
70	Extracranial growth of glioblastoma multiforme. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1521-1523.	1.5	25
71	Immunotherapy for glioblastoma: going viral. <i>Nature Medicine</i> , 2018, 24, 1094-1096.	30.7	25
72	KLF4/409Q mutated meningiomas show enhanced hypoxia signaling and respond to mTORC1 inhibitor treatment. <i>Acta Neuropathologica Communications</i> , 2020, 8, 41.	5.2	25

#	ARTICLE	IF	CITATIONS
73	Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. <i>Scientific Reports</i> , 2018, 8, 208.	3.3	24
74	Proteomic Analysis Implicates Vimentin in Glioblastoma Cell Migration. <i>Cancers</i> , 2019, 11, 466.	3.7	24
75	Targeting glioma-initiating cells via the tyrosine metabolic pathway. <i>Journal of Neurosurgery</i> , 2021, 134, 721-732.	1.6	23
76	Agent-based computational modeling of glioblastoma predicts that stromal density is central to oncolytic virus efficacy. <i>IScience</i> , 2022, 25, 104395.	4.1	23
77	Experimental therapies. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 183-197.	1.8	22
78	Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells.. <i>Oncolimmunology</i> , 2018, 7, e1407897.	4.6	22
79	A vaccine from plant virus proteins. <i>Nature Nanotechnology</i> , 2016, 11, 214-215.	31.5	21
80	Glioma and microglia, a double entendre. <i>Nature Immunology</i> , 2016, 17, 1240-1242.	14.5	20
81	Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. <i>Neurosurgery</i> , 2019, 85, E607-E608.	1.1	20
82	A Platinum(IV) Prodrugâ€™Perfluoroaryl Macrocylic Peptide Conjugate Enhances Platinum Uptake in the Brain. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 6741-6747.	6.4	20
83	FASN Is a Biomarker Enriched in Malignant Glioma-Derived Extracellular Vesicles. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1931.	4.1	20
84	Multicolumn Infusion of Gene Therapy Cells into Human Brain Tumors: Technical Report. <i>Neurosurgery</i> , 2000, 46, 663-669.	1.1	19
85	Potentiating oncolytic viral therapy through an understanding of the initial immune responses to oncolytic viral infection. <i>Current Opinion in Virology</i> , 2015, 13, 25-32.	5.4	19
86	Immune Escape Mediated by Exosomal PDâ€™L1 in Cancer. <i>Advanced Biology</i> , 2020, 4, e2000017.	3.0	19
87	Viruses in cancer therapy â€™ from benchwarmers to quarterbacks. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 657-658.	27.6	17
88	Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy. <i>Oncolytic Virotherapy</i> , 2015, 4, 183.	6.0	16
89	The Current Landscape of Oncolytic Herpes Simplex Viruses as Novel Therapies for Brain Malignancies. <i>Viruses</i> , 2021, 13, 1158.	3.3	16
90	How Much Is Enough? The Question of Extent of Resection in Glioblastoma Multiforme. <i>World Neurosurgery</i> , 2014, 82, e109-e110.	1.3	15

#	ARTICLE	IF	CITATIONS
91	Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone. <i>Journal of Neuro-Oncology</i> , 2017, 135, 581-591.	2.9	15
92	Extracellular Vesicles Induce Mesenchymal Transition and Therapeutic Resistance in Glioblastomas through NF- κ B/STAT3 Signaling. <i>Advanced Biology</i> , 2020, 4, 1900312.	3.0	15
93	Current State of Immune-Based Therapies for Glioblastoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e132-e139.	3.8	13
94	Therapeutic cancer vaccines for pediatric malignancies: advances, challenges, and emerging technologies. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab027.	0.7	13
95	One size should not fit all: advancing toward personalized glioblastoma therapy. <i>Discovery Medicine</i> , 2015, 19, 471-7.	0.5	13
96	Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. <i>Neuro-Oncology</i> , 2022, 24, 1140-1149.	1.2	13
97	Redesigned reporter gene for improved proton exchange-based molecular MRI contrast. <i>Scientific Reports</i> , 2020, 10, 20664.	3.3	12
98	Frameless Stereotactic Navigation during Insular Glioma Resection using Fusion of Three-Dimensional Rotational Angiography and Magnetic Resonance Imaging. <i>World Neurosurgery</i> , 2019, 126, 322-330.	1.3	11
99	Targeting Glioblastoma Using a Novel Peptide Specific to a Deglycosylated Isoform of Brevican. <i>Advanced Therapeutics</i> , 2021, 4, 2000244.	3.2	11
100	Hypoxic Roadmap of Glioblastoma—Learning about Directions and Distances in the Brain Tumor Environment. <i>Cancers</i> , 2020, 12, 1213.	3.7	10
101	Preliminary results of the abemaciclib arm in the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGH): A phase II platform trial using Bayesian adaptive randomization. <i>Journal of Clinical Oncology</i> , 2021, 39, 2014-2014.	1.6	10
102	Target receptor identification and subsequent treatment of resected brain tumors with encapsulated and engineered allogeneic stem cells. <i>Nature Communications</i> , 2022, 13, 2810.	12.8	10
103	Pneumatosis Intestinalis After Molecular-Targeted Therapy. <i>World Neurosurgery</i> , 2019, 125, 312-315.	1.3	9
104	Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models. , 2022, 10, e003368.		9
105	Design of a Microfluidic Chip for Magnetic-Activated Sorting of One-Bead-One-Compound Libraries. <i>ACS Combinatorial Science</i> , 2016, 18, 271-278.	3.8	8
106	Oncolytic HSV Vectors and Anti-Tumor Immunity. <i>Current Issues in Molecular Biology</i> , 2021, 41, 381-468.	2.4	8
107	Oncolytic Virus Therapy Alters the Secretome of Targeted Glioblastoma Cells. <i>Cancers</i> , 2021, 13, 1287.	3.7	8
108	Expanded phase I study of intratumoral Ad-RTS-hIL-12 plus oral vedolimex: Tolerability and survival in recurrent glioblastoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2044-2044.	1.6	8

#	ARTICLE	IF	CITATIONS
109	Response to energy depletion: miR-451/AMPK loop. <i>Oncotarget</i> , 2015, 6, 17851-17852.	1.8	7
110	National Institute of Neurological Disorders and Stroke: current funding status, opportunities, challenges, emerging scientific advances, and recommendations for neurosurgery. <i>Journal of Neurosurgery</i> , 2020, 133, 1264-1269.	1.6	7
111	From Localization to Pathways: The Continuing Evolution of Diffusion Tensor Imaging. <i>World Neurosurgery</i> , 2014, 82, e47-e48.	1.3	6
112	Awake right hemisphere brain surgery. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1921-1927.	1.5	6
113	Adult Tethered Cord Syndrome Following Chiari Decompression. <i>World Neurosurgery</i> , 2018, 112, 205-208.	1.3	6
114	Biographies of international women leaders in neurosurgery. <i>Neurosurgical Focus</i> , 2021, 50, E19.	2.3	5
115	Evaluating the benefit of adaptive randomization in the CC-115 arm of the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A phase II randomized Bayesian adaptive platform trial in newly diagnosed MGMT unmethylated glioblastoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2006-2006.	1.6	5
116	Guided genes for tumor warfare. <i>Nature Biotechnology</i> , 2002, 20, 235-236.	17.5	4
117	Skull Base Chordomas and Chondrosarcomas: A Population-Based Analysis. <i>World Neurosurgery</i> , 2015, 83, 468-470.	1.3	4
118	Evaluation of controlled IL-12 in combination with a PD-1 inhibitor in subjects with recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2020-2020.	1.6	4
119	CTNI-05. PRELIMINARY RESULTS OF THE NERATINIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION. <i>Neuro-Oncology</i> , 2021, 23, vi59-vi59.	1.2	4
120	CTIM-20. FINAL RESULTS OF CONTROLLED IL-12 MONOTHERAPY AND IN COMBINATION WITH PD-1 INHIBITOR IN ADULT SUBJECTS WITH RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi54-vi54.	1.2	4
121	IMMU-26. SAFETY AND EFFICACY OF PVSRIPO IN RECURRENT GLIOBLASTOMA: LONG-TERM FOLLOW-UP AND INITIAL MULTICENTER RESULTS. <i>Neuro-Oncology</i> , 2021, 23, vi97-vi97.	1.2	4
122	First-in-human CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) in patients with recurrent high-grade glioma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2009-2009.	1.6	3
123	Controlled IL-12 in combination with a PD-1 inhibitor subjects with recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2510-2510.	1.6	3
124	Low-Grade Gliomas and Quality of Life. <i>World Neurosurgery</i> , 2014, 82, e133-e134.	1.3	2
125	Neoplasm Development After Stereotactic Radiosurgery for Arteriovenous Malformations. <i>World Neurosurgery</i> , 2014, 82, 304-306.	1.3	2
126	Awake Craniotomy and Intraoperative MRI for Maximal Safe Resection in a Case of an Extensive Left Frontal and Insular Low-grade Glioma: 3-Dimensional Operative Video. <i>Operative Neurosurgery</i> , 2015, 11, 578-578.	0.8	2

#	ARTICLE	IF	CITATIONS
127	Modeling Cytomegalovirus Infection in Mouse Tumor Models. <i>Frontiers in Oncology</i> , 2015, 5, 61.	2.8	2
128	ATIM-15. A PHASE 1 STUDY OF Ad-RTS-hIL-12 + VELEDIMEX IN ADULTS WITH RECURRENT GLIOBLASTOMA: DOSE DETERMINATION WITH UPDATED OVERALL SURVIVAL. <i>Neuro-Oncology</i> , 2018, 20, vi3-vi4.	1.2	2
129	Evolution of the Neurosurgeon's Role in Clinical Trials for Glioblastoma: A Systematic Overview of the Clinicaltrials.Gov Database. <i>Neurosurgery</i> , 2021, 89, 196-203.	1.1	2
130	Neurosurgery Research and Education Foundation funding conversion to National Institutes of Health funding. <i>Journal of Neurosurgery</i> , 2022, 136, 287-294.	1.6	2
131	Cytomegalovirus infection of glioblastoma cells leads to NF- κ B dependent upregulation of the c-MET oncogenic tyrosine kinase. <i>Cancer Letters</i> , 2021, 513, 26-35.	7.2	2
132	Effect of controlled intratumoral viral delivery of Ad-RTS-hIL-12 + oral veledimex in subjects with recurrent or progressive glioma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2052-2052.	1.6	2
133	Feasibility and conduct of INSIGHT, a platform trial of patients with glioblastoma using Bayesian adaptive randomization.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2012-2012.	1.6	2
134	Tannous et al. Respond:. <i>Molecular Therapy</i> , 2009, 17, 1311-1312.	8.2	1
135	Image-Guided Maximal Resection of Intrinsic Tumors. <i>World Neurosurgery</i> , 2014, 82, 604-605.	1.3	1
136	A cross-talk network that facilitates tumor virotherapy. <i>Nature Medicine</i> , 2015, 21, 426-427.	30.7	1
137	No Free Lunch: Secondary Neoplasms After Stereotactic Radiation. <i>World Neurosurgery</i> , 2015, 83, 330-331.	1.3	1
138	Academic Productivity in Today's Training Climate: A Fellowship's Impact. <i>World Neurosurgery</i> , 2015, 83, 328-329.	1.3	1
139	DDIS-26. BTP-7, A NOVEL PEPTIDE FOR THERAPEUTIC TARGETING OF MALIGNANT BRAIN TUMORS. <i>Neuro-Oncology</i> , 2018, 20, vi74-vi74.	1.2	1
140	Cytomegalovirus Encephalopathy during Brain Tumor Irradiation. <i>Clinical Cancer Research</i> , 2020, 26, 3077-3078.	7.0	1
141	The Evolving Role of Neurosurgical Intervention for Central Nervous System Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 63-75.	2.2	1
142	Hypofractionated (HRT) versus standard (SRT) radiotherapy with or without temozolomide (T) for elderly patients with glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2014, 32, 2065-2065.	1.6	1
143	Final results of controlled IL-12 monotherapy in adults with grade III or IV gliomas.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3040-3040.	1.6	1
144	Modulation of Natural Killer Cell Activity in the Setting of Oncolytic Virotherapy and with a Chimeric Antigen Receptor. <i>Blood</i> , 2015, 126, 210-210.	1.4	1

#	ARTICLE	IF	CITATIONS
145	Demonstration of anti-tumor immunity via intratumoral regulated platform ad-RTS-hIL-12 in advanced breast cancer and recurrent glioblastoma patients.. Journal of Clinical Oncology, 2018, 36, 3038-3038.	1.6	1
146	ALLELE: A consortium for prospective genomics and functional diagnostics to guide patient care and trial analysis in newly-diagnosed glioblastoma.. Journal of Clinical Oncology, 2018, 36, 2003-2003.	1.6	1
147	CTIM-18. LUMINOS-101: INITIAL SAFETY AND TOLERABILITY OF PVSRIPO AND PEMBROLIZUMAB COMBINATION THERAPY IN RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi53-vi54.	1.2	1
148	CTIM-13. PHASE 1 CLINICAL TRIAL OF ONCOLYTIC VIRAL IMMUNOTHERAPY WITH CAN-2409 + VALACYCLOVIR IN COMBINATION WITH NIVOLUMAB AND STANDARD OF CARE (SOC) IN NEWLY DIAGNOSED HIGH-GRADE GLIOMA (HGG). Neuro-Oncology, 2021, 23, vi52-vi52.	1.2	1
149	The Current State of Glioma Data Registries. Neuro-Oncology Advances, 0, , .	0.7	1
150	Targeting Glioblastoma Invasion with GSK-3 inhibitors: Rapid Effects on the EMT Marker Vimentin. Canadian Journal of Neurological Sciences, 2014, 41, S1-S2.	0.5	0
151	Predicting Outcomes: Recursive Partitioning Analysis (RPA) Prognostic Algorithm for Patients with Metastatic Sarcoma to the Brain. World Neurosurgery, 2014, 82, 1030-1032.	1.3	0
152	Who Benefits from Surgery for Brain Metastases?. World Neurosurgery, 2014, 82, e115-e116.	1.3	0
153	ATPS-08DISCOVERY OF NOVEL GLIOMA-TARGETING PEPTIDES USING A HIGH-THROUGHPLUT MICROFLUIDIC MAGNETIC-ACTIVATED SORTER. Neuro-Oncology, 2015, 17, v19.4-v19.	1.2	0
154	ATPS-98MONITORING ONCOLYTIC HSV-1 WITH NON-INVASIVE BIOLUMINESCENCE. Neuro-Oncology, 2015, 17, v40.1-v40.	1.2	0
155	IMPS-21EFFECT OF rQNestin 34.5 ONCOLYTIC HERPES VIRUS ON IMMUNE CHECKPOINT GENE EXPRESSION IN GLIOBLASTOMA CELLS AND EVALUATION OF THERAPEUTIC EFFICACY. Neuro-Oncology, 2015, 17, v117.4-v118.	1.2	0
156	CBIO-12. SIX EXTRACELLULAR VESICLE RELATED GENES CAN EXPLAIN THE PRO-TUMORIGENIC BEHAVIOR OF HETEROGENEOUS HIGH GRADE GLIOMAS. Neuro-Oncology, 2016, 18, vi37-vi37.	1.2	0
157	IMST-05. NOVEL CAR-T CELLS TARGETING THE EXTRACELLULAR MATRIX OF GLIOBLASTOMA INDUCE STRONG ANTI-TUMOR IMMUNE RESPONSE. Neuro-Oncology, 2016, 18, vi86-vi87.	1.2	0
158	IMMU-12. THE HISTONE DEACETYLASE INHIBITOR VALPROIC ACID AUGMENTS THE SUSCEPTIBILITY OF ONCOLYTIC VIRUS-INFECTED GLIOBLASTOMA CELLS TO PD-1 BLOCKADE THERAPY. Neuro-Oncology, 2017, 19, vi115-vi115.	1.2	0
159	IMMU-10. EXPRESSION OF PD-L2, IN GLIOBLASTOMA; IMPLICATIONS AS A BIOMARKER FOR IMMUNOTHERAPY. Neuro-Oncology, 2017, 19, vi114-vi114.	1.2	0
160	Endoscopic Endonasal Resection of a Suprasellar Pituitary Adenoma Mimicking Tuberculum Sellae Meningioma in a Patient with an Intrasellar Persistent Trigeminal Artery. Journal of Neurological Surgery, Part B: Skull Base, 2018, 79, S285-S286.	0.8	0
161	INNV-13. ALLELE: A CONSORTIUM FOR PROSPECTIVE GENOMICS AND FUNCTIONAL DIAGNOSTICS TO GUIDE PATIENT CARE AND TRIAL ANALYSIS IN NEWLY-DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi140-vi141.	1.2	0
162	TMOD-14. A PATIENT-DERIVED CANCER CELL LINE ATLAS OF PRIMARY AND METASTATIC CENTRAL NERVOUS SYSTEM TUMORS. Neuro-Oncology, 2018, 20, vi271-vi271.	1.2	0

#	ARTICLE	IF	CITATIONS
163	IMMU-02. ONCOLYTIC HSV THERAPY ENHANCES GLIOBLASTOMA CONTROL VIA THE EXPANSION OF FUNCTIONAL TUMOR-SPECIFIC T CELLS AND MODULATION OF MYELOID CELL POPULATION. <i>Neuro-Oncology</i> , 2018, 20, vi121-vi121.	1.2	0
164	EXTH-53. IN VIVO QUANTITATIVE ANALYSIS OF ONCOLYTIC VIRUS-TUMOR KINETICS. <i>Neuro-Oncology</i> , 2018, 20, vi96-vi96.	1.2	0
165	ATIM-32. PERSONALIZED NEOANTIGEN-TARGETING VACCINE GENERATES ROBUST SYSTEMIC AND INTRATUMORAL T CELL RESPONSES IN GLIOBLASTOMA (GBM) PATIENTS. <i>Neuro-Oncology</i> , 2018, 20, vi8-vi8.	1.2	0
166	46. PAN-CANCER ANALYSIS OF ORTHOTOPIC PATIENT DERIVED XENOGRAFTS FROM BRAIN METASTASES. <i>Neuro-Oncology Advances</i> , 2020, 2, ii9-ii9.	0.7	0
167	Role of surgery for glioblastoma: response to letters from Dr. Gerritsen and his colleagues and Dr. Vargas Lopez. <i>Neuro-Oncology</i> , 2021, 23, 506-507.	1.2	0
168	Introduction. Gene and viral therapy for glioblastoma multiforme. <i>Neurosurgical Focus</i> , 2021, 50, E1.	2.3	0
169	The 1994 National Cancer Institute's strategy to fund multi-institutional, multidisciplinary consortia to design and conduct early phase clinical trials in patients with high grade gliomas.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2003-2003.	1.6	0
170	CLRM-05. DRUG-RELEASING MICRODEVICES TO PREDICT RESPONSES TO TARGETED THERAPIES IN PATIENTS WITH GLIOMAS. <i>Neuro-Oncology Advances</i> , 2021, 3, iv2-iv2.	0.7	0
171	Virotherapy treatment of central nervous system tumors. , 2022, , 55-71.		0
172	Ascending dose trials of a retroviral replicating vector (Toca 511) in patients with recurrent high-grade glioma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3078-3078.	1.6	0
173	Evaluation of controlled IL-12 as monotherapy in subjects with recurrent GBM.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2053-2053.	1.6	0
174	EXTH-61. MODULATION OF THE IL-27 RECEPTOR SIGNALING PATHWAY IN GLIOBLASTOMA AND ONCOLYTIC VIROTHERAPY. <i>Neuro-Oncology</i> , 2021, 23, vi177-vi177.	1.2	0
175	EXTH-81. STING ACTIVATION PROMOTES ROBUST IMMUNE RESPONSE AND TUMOR REGRESSION IN GLIOBLASTOMA MODELS. <i>Neuro-Oncology</i> , 2021, 23, vi182-vi182.	1.2	0
176	CTNI-40. EVALUATING FEASIBILITY AND EFFICIENCY OF PHASE II ADAPTIVE PLATFORM TRIAL DESIGNS BASED ON THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT) EXPERIENCE. <i>Neuro-Oncology</i> , 2021, 23, vi68-vi69.	1.2	0
177	CSIG-19. DISRUPTION OF DNA DAMAGE RESPONSE MODULATES THE EFFICACY OF LOCAL IMMUNOTHERAPIES IN EXPERIMENTAL GLIOMA. <i>Neuro-Oncology</i> , 2021, 23, vi37-vi37.	1.2	0
178	TAMI-35. DETECTING SINGLE-CELL INTERACTIONS IN ORGANOTYPIC CULTURES OF GLIOBLASTOMA USING BARCODED RABIES VIRUS. <i>Neuro-Oncology</i> , 2021, 23, vi205-vi205.	1.2	0
179	DDRE-18. THERAPEUTIC EFFECTS OF TASQUINIMOD ON GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi78-vi78.	1.2	0
180	Abstract 6388: The effect of oncolytic virus therapy on neoantigen specific immune responses. <i>Cancer Research</i> , 2022, 82, 6388-6388.	0.9	0